Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.74+0.01 (+0.07%)
Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%
Dr Reddys Laboratories r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was ₹24.06B, down 12.1% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is ₹27.38B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹24.06B | -12.1% |
| FY2025 | Mar 31, 2025 | ₹27.38B | +19.7% |
| FY2024 | Mar 31, 2024 | ₹22.87B | +18.0% |
| FY2023 | Mar 31, 2023 | ₹19.38B | +10.9% |
| FY2022 | Mar 31, 2022 | ₹17.48B | +5.7% |
| FY2021 | Mar 31, 2021 | ₹16.54B | +7.3% |
| FY2020 | Mar 31, 2020 | ₹15.41B | -1.3% |
| FY2019 | Mar 31, 2019 | ₹15.61B | -14.6% |
| FY2018 | Mar 31, 2018 | ₹18.27B | -6.6% |
| FY2017 | Mar 31, 2017 | ₹19.55B | +9.6% |
| FY2016 | Mar 31, 2016 | ₹17.83B | – |
See a number that looks wrong?